Can certain bacteroides strains resist tigecycline?

Can certain bacteroides strains resist tigecycline?

Certain Bacteroides strains carry tet(X) genes that encode enzymes capable of inactivating tigecycline, conferring resistance to the drug. tet(X) genes have been reported in Bacteroides species isolated from both clinical and environmental samples.

How common is tigecycline resistance in Bacteroides?

Resistance rates remain low in most clinical surveys, but isolated outbreaks and increasing reports from animal and environmental reservoirs raise concern. Monitoring programs show prevalence below 1% in many regions, but higher rates appear in areas where tetracyclines are heavily used in agriculture.

What mechanism explains tigecycline resistance in Bacteroides?

The tet(X) genes produce flavin-dependent monooxygenases that chemically modify the core tetracycline ring, destroying its ability to bind ribosomes. This enzymatic inactivation differs from efflux pumps or ribosomal protection proteins that cause standard tetracycline resistance. tet(X) variants such as tet(X3) and tet(X4) show higher activity against tigecycline.

When did researchers first detect tet(X) genes in Bacteroides?

Researchers identified tet(X) genes in Bacteroides fragilis clinical isolates as early as the 2000s. More virulent tet(X4) variants emerged in Enterobacteriaceae from animal sources around 2019, raising fears that these genes could eventually transfer into anaerobic bacteria such as Bacteroides.

Can biosimilars or alternatives enter before tigecycline-related patents expire?

Tigecycline itself is an antibiotic rather than a biologic, so biosimilars are not applicable. Generic versions entered the market after patent expiry in 2014.